Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
11 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
ECUPHAR from Oostkamp, company number BE0476255350, closed financial year 2025 with a result of € 1.6 million after tax. For that financial year ECUPHAR recorded revenue of € 22.9 million and equity of € 83.3 million. Compared with financial year 2023, the result moved from € 7.7 million to € 1.6 million. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 31, 2026.
€ 83.3 million
▲ 21% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 1.6 million
▼ 79% vs 2023
Profit after tax over the fiscal year.
€ 1.7 million
▼ 49% vs 2023
Cash and bank balances on the last day of the fiscal year.
€ 13 million paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
21.4
▲ 1.6 vs 2023
Average over the fiscal year, from the social balance sheet.
€ 2.4 million
▲ 11% vs 2023
€ 111,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 8,187
▼ 33% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 13.7 million
▲ € 10.4 million vs 2023
€ 2.4 million is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.
€ 6.4 million
▲ 49% vs 2023
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 141 days on average.
€ 523,955
▼ 7% vs 2023
Taxes, VAT and social contributions still to pay.
| 2021 | 2022 | 2023 | 2025 | Change 2023 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 18,585,370 | € 17,760,577 | € 21,299,908 | € 22,873,858 | ▲ 7% |
| Profit after taxes | € 342,703 | € -2,880,382 | € 7,738,257 | € 1,637,037 | ▼ 79% |
| Equity | € 67,733,120 | € 64,852,739 | € 68,590,996 | € 83,292,736 | ▲ 21% |
| Total debts | € 69,687,157 | € 83,738,677 | € 93,236,722 | € 80,829,681 | ▼ 13% |
| Cash | € 5,356,984 | € 5,600,743 | € 3,400,480 | € 1,738,231 | ▼ 49% |
| Retained profit | € 30,529,813 | € 27,649,431 | € 31,387,688 | € 46,089,429 | ▲ 47% |
| Dividend | € 9,500,000 | € 0 | € 4,000,000 | € 13,000,000 | ▲ 225% |
| Bank debt | € 11,614,086 | € 9,859,816 | € 3,375,000 | € 13,729,780 | ▲ € 10.4 million |
| Balance sheet total | € 137,439,177 | € 148,720,051 | € 161,827,717 | € 164,122,417 | ▲ 1% |
| Employees (FTE) | 22.1 | 21.5 | 19.8 | 21.4 | ▲ 1.6 |
Key figures of ECUPHAR, fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ECUPHAR?
What happened at ECUPHAR in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Jenny Winter stepped down as director. NBB
- Christopher Brewster stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 1.6 million (▼ 79% vs 2023). Source: NBB ↗
- Jenny Winter became a director. NBB
- Christopher Brewster became a director. NBB
- New establishment in Oostkamp. KBO
- Start of the company according to the CBE. KBO
In short
From € 342,703 profit in 2021 to € 1.6 million profit in 2025.
Paid € 15,780 in corporate taxes since 2021.
Best year ever: 2023, with € 7.7 million profit.
Paid out € 26.5 million in dividends to the owners in total.
Management
It owns 100% of Ornis, 100% of ECUPHAR VETERINARY PRODUCTS, 100% of ECUPHAR VETERINARIA SLU, 100% of EURACON PHARMA CONSULTING UND TRADING, 100% of Ecuphar GmbH and 100% of ECUPHAR ITALIA itself.
Directors
According to the 2025 annual accounts
Jenny Winter
Director
since 2024 · until 2029
Christopher Brewster
Director
since 2023 · until 2029
Establishments
Establishment units
Physical locations of this company
Legeweg 157 box I
8020 Oostkamp
Legeweg 157 box i
8020 Oostkamp
Active since 19 April 2002
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 11 companies are registered at this address.
All companies at this address →DIRAME ORTHO
€ 335,440 gross margin · 2025
EHC Invest
€ 82,089 revenue · 2025
Jimber
€ 757,960 gross margin · 2025
Vetdis Holding
€ 120,000 revenue · 2025
LAUNCHPAD EUROPE
€ 10,335 gross margin · 2025
+6 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0476.255.350
- VAT number
- BE 0476.255.350
- Registered office
- Legeweg 157 bus I, 8020 Oostkamp
- Names & denominations
- ECUPHAR · Cardon Pharmaceuticals
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 6 December 2001
- Peppol
- Active · Active since 5 Jun 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten
Public relationsbureaus
Activiteiten van adviesbureaus op het gebied van public relations en communicatie
Adviesbureaus op het gebied van public relations en communicatie